In June 2024 Merck Animal Health (known as MSD Animal Health outside the US and Canada) announced that the USDA has approved NOBIVAC NXT Canine Flu H3N2, its “next-level solution” to protect dogs against the “ongoing threat” of canine influenza. The product is expected to be available at veterinary clinicals and hospitals nationwide later in the summer. Canine influenza, also known as dog flu, is a serious respiratory illness that transmits easily between dogs. The vaccine leverages RNA-partcile technology to enable a precise immune response against a range of viral and bacterial pathogens.
NOBIVAC NXT Canine Flu H3N2
NOBIVAC NXT Canine Flu H3N2 is the “first and only” canine influenza vaccine based on Merck Animal Health’s RNA-particle technology platform. It is a nonadjuvanted, low volume 0.5 mL dose vaccine that “harnesses the natural ability of the immune system to generate a robust response without compromising comfort or safety”. It is indicated for the vaccination of healthy dogs aged 8 weeks or older.
In response to the emergence of the canine influenza H3N2 epidemic in the US in 2015, Merck Animal Health made its monovalent H3N2 vaccine available to protect dogs against the disease. In 2016 it received a fully licensed bivalent and monovalent H3N2 vaccine.
A groundbreaking advancement
Dr Christine Royal, vice president, companion animal and equine business unit, Merck Animal Health, is “beyond proud” that the team is introducing the latest vaccine with “NXT-level technology”.
“This is a groundbreaking advancement in our vaccine pipeline designed to meet the evolving needs of veterinarians and pet owners alike. With over 70 years of innovation and commitment to animal health, our new NOBOVAC NXT technology will continue to lead the way in providing breakthrough solutions for the prevention of disease in animals.”
Dr Ian Tarpey, vice president, research and development, Merck Animal Health, stated that “as a leader in innovation and trusted advocate for disease prevention”, the team is using its leadership and expertise to “make medicines that help keep pets safe”.
“The NOBIVAC NXT innovation represents a major advancement in vaccine technology and furthers our commitment to animal care by helping veterinarians protect pets from significant disease and ultimately, improve their lives by preventing health issues.”
Dr Meg Conlon, executive director, veterinary professional services, Merck Animal Health, emphasised that “vaccination is the best form of protection against this highly transmissible disease” that can have a “widespread impact”.
“Pets have become part of the family and are integrated into so many aspects of our lives, which makes vaccination even more crucial. At Merck Animal Health, we continue to stress the importance of preventative care to keep our beloved pets healthy and protected from potential illness.”
For more on veterinary vaccines and protecting animal health, why not join us at the Congress in Barcelona this October? Don’t forget to subscribe to our weekly newsletters here.
